DK2442826T3 - Influenzavaccine, sammensætning og fremgangsmåder til anvendelse - Google Patents

Influenzavaccine, sammensætning og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK2442826T3
DK2442826T3 DK09846104.9T DK09846104T DK2442826T3 DK 2442826 T3 DK2442826 T3 DK 2442826T3 DK 09846104 T DK09846104 T DK 09846104T DK 2442826 T3 DK2442826 T3 DK 2442826T3
Authority
DK
Denmark
Prior art keywords
influenza
composition
gene
mutated
strain
Prior art date
Application number
DK09846104.9T
Other languages
English (en)
Inventor
Sylvie Alonso
Rui Li
Vincent Chow
Camille Locht
Original Assignee
Univ Singapore
Inst Nat Santé Et De La Rech Médicale
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Singapore, Inst Nat Santé Et De La Rech Médicale, Pasteur Institut filed Critical Univ Singapore
Application granted granted Critical
Publication of DK2442826T3 publication Critical patent/DK2442826T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (15)

1. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr, hvori sammensætningen omfatter en svækket Bordetella stamme, hvori den svækkede Bordetella stamme er en muteret Bordetella stamme omfattende: - et muteret pertussistoksin(ptx)-gen, - et deleteret eller muteret dermonekrose(dnt)-gen, og - et heterologt ampG-gen, og hvori den muterede Bordetella stamme ikke omfatter en heterolog ekspressionsplatform, der bærer heterologe antigener, hvilken heterologe ekspressionsplatform anvendes til at levere de heterologe antigener til et pattedyrs luftvejsslimhinde.
2. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge krav 1, hvori Bordetella stammen omfatter en Bordetella pertussis stamme.
3. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge krav 1 eller 2, hvori det muterede ptx-gen koder et PTX-protein, hvis S1 - del er enzymatisk inaktiv, men stadig immunologisk aktiv.
4. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge krav 3, hvori mutationen af ptx-genet resulterer i substitution af en aminosyre involveret i substratbinding.
5. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge krav 4, hvori substitution af aminosyren involveret i substratbindingen omfatter K9R.
6. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge ethvert af krav 3-5, hvori mutationen af ptx-genet resulterer i substitution af en aminosyre involveret i katalyse.
7. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge krav 6, hvori substitution af aminosyren involveret i katalyse omfatter E129G.
8. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge ethvert af krav 1-7, hvori dnt-genet er deleteret.
9. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge ethvert af krav 1-7, hvori dnt-genet er muteret.
10. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge krav 9, hvori det muterede dnt-gen koder for et protein, der har en mangelfuld DNT-enzymatisk aktivitet, hvori det muterede dnt-gen muteres ved punktmutation, og hvori det muterede dnt-gen er muteret for at kode Ala-1305 i stedet for Cys-1305.
11. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge ethvert af krav 1-10, hvori det heterologe ampG-gen erstatter det endogene Bordetella ampG-gen.
12. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge krav 11, hvori det heterologe ampG-gen er ampG-genet af en E. coli stamme.
13. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge krav 11 eller 12, hvori den muterede Bordetella stamme eksprimerer mindre end 1% residualtracheal cytotoksin (TCT) aktivitet.
14. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge ethvert af krav 1-13, hvori den svækkede Bordetella stamme er stammen identificeret ved deponeringsnummeret CNCM I-3585 deponeret under Budapest Traktaten den 9. marts 2006 hos Collection Nationale de Cultures de Microorganismes (CNCM) i Paris, Frankrig,.
15. Sammensætning til anvendelse ved behandling eller forebyggelse af en influenzainfektion i et pattedyr ifølge ethvert af krav 1-14, hvori den muterede Bordetella stamme yderligere omfatter et muteret Bvg-reguleret gen valgt blandt et mangelfuldt adenylatcyklase(AC)-gen, et mangelfuldt lipopolysakkarid(LPS)-gen og et mangelfuldt filamenthæmagglutinin(FHA)-gen.
DK09846104.9T 2009-06-15 2009-06-15 Influenzavaccine, sammensætning og fremgangsmåder til anvendelse DK2442826T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2009/007153 WO2010146414A1 (en) 2009-06-15 2009-06-15 Influenza vaccine, composition, and methods of use

Publications (1)

Publication Number Publication Date
DK2442826T3 true DK2442826T3 (da) 2015-09-21

Family

ID=43355934

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09846104.9T DK2442826T3 (da) 2009-06-15 2009-06-15 Influenzavaccine, sammensætning og fremgangsmåder til anvendelse

Country Status (8)

Country Link
US (3) US9526778B2 (da)
EP (2) EP2442826B1 (da)
JP (1) JP5551774B2 (da)
CN (1) CN102802665B (da)
CA (1) CA2765364C (da)
DK (1) DK2442826T3 (da)
SG (1) SG176532A1 (da)
WO (1) WO2010146414A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1994139B1 (en) * 2006-03-10 2016-07-13 Institut Pasteur De Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
EP2442826B1 (en) * 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use
AU2012331646B2 (en) * 2011-11-02 2017-03-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Effect of an attenuated Bordetella strain against allergic disease
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
WO2016001907A1 (en) * 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
US9655959B2 (en) 2014-10-01 2017-05-23 National University Of Singapore Adenylate cyclase deficient bordetella strains
JP6993984B2 (ja) 2016-03-29 2022-02-03 アンスティチュ パスツール ドゥ リール 変異ボルデテラ菌株および使用方法
WO2019077028A1 (en) 2017-10-18 2019-04-25 Institut Pasteur De Lille BORDETELLA STRAINS EXPRESSING SERO-TYPE FIMBRIAE 3
TWI657824B (zh) * 2017-12-29 2019-05-01 財團法人生物技術開發中心 抗流感之通用疫苗
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2024018061A1 (en) * 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Use of bordetella strains for the treatment of chronic obstructive pulmonary disease

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2718750B1 (fr) 1994-04-19 1996-06-14 Pasteur Institut Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants.
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
FR2754543B1 (fr) 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
JP4426091B2 (ja) 1997-09-05 2010-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンを含有する水中油型エマルション
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999027961A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
WO2001021152A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
CN1391483A (zh) 1999-09-24 2003-01-15 史密丝克莱恩比彻姆生物有限公司 作为佐剂的聚氧乙烯脱水山梨醇酯和辛苯昔醇组合及其在疫苗中的应用
CA2396871A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
WO2002026757A2 (en) 2000-09-26 2002-04-04 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US7527802B2 (en) 2001-02-13 2009-05-05 The United States Of America As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
WO2002074244A2 (en) 2001-03-19 2002-09-26 Iomai Corporation Transcutaneous immunostimulation
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2840319B1 (fr) 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
AU2004229527B2 (en) 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions
EP1994139B1 (en) 2006-03-10 2016-07-13 Institut Pasteur De Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
ES2562774T3 (es) * 2006-11-15 2016-03-08 Folia Biotech Inc. Vacunas para la gripe basadas en el virus del mosaico de la papaya
US20100104533A1 (en) * 2007-06-18 2010-04-29 Carter William A Early intervention of viral infection with immune activators
JP5678034B2 (ja) 2009-04-28 2015-02-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アレルゲン駆動性気道病態の予防または治療のためのワクチン
EP2442826B1 (en) * 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use

Also Published As

Publication number Publication date
CN102802665B (zh) 2015-11-25
US20230364217A1 (en) 2023-11-16
EP2442826A1 (en) 2012-04-25
EP2442826B1 (en) 2015-07-08
US9526778B2 (en) 2016-12-27
CA2765364C (en) 2015-05-26
EP2944320A1 (en) 2015-11-18
JP2012530128A (ja) 2012-11-29
AU2009348207A1 (en) 2012-01-19
CN102802665A (zh) 2012-11-28
US20170106074A1 (en) 2017-04-20
US20120121647A1 (en) 2012-05-17
CA2765364A1 (en) 2010-12-23
EP2442826A4 (en) 2012-12-12
SG176532A1 (en) 2012-01-30
WO2010146414A1 (en) 2010-12-23
JP5551774B2 (ja) 2014-07-16

Similar Documents

Publication Publication Date Title
US20230364217A1 (en) Influenza vaccine, composition, and methods of use
AU2012331646B2 (en) Effect of an attenuated Bordetella strain against allergic disease
CN115190911B (zh) 对sars冠状病毒2具有免疫原性的组合物、其制备方法和用途
US9950059B2 (en) Immunogenic composition
WO2022037248A1 (en) Live attenuated sars-cov-2 virus immunogenic compositions, methods of making and using
US20230089695A1 (en) Compositions immunogenic against sars coronavirus 2, methods of making, and using thereof
AU2009348207B2 (en) Influenza vaccine, composition, and methods of use
JP5995329B2 (ja) インフルエンザワクチン、組成物、および使用方法
WO2020097923A1 (en) Live attenuated influenza b virus compositions methods of making and using thereof
JP2016172779A (ja) インフルエンザワクチン、組成物、および使用方法
US20240050558A1 (en) Compositions immunogenic against influenza and sars coronavirus 2, methods of making and using thereof
CN116635068A (zh) 针对流感和sars冠状病毒2具有免疫原性的组合物、其制备和使用方法
Falkeborn et al. Jacobs Journal of Vaccines and Vaccination